National Asset Management Inc. Makes New $572,000 Investment in The Chemours Company (NYSE:CC)

National Asset Management Inc. bought a new position in The Chemours Company (NYSE:CCGet Rating) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 18,140 shares of the specialty chemicals company’s stock, valued at approximately $572,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. AdvisorNet Financial Inc lifted its position in Chemours by 63.2% in the first quarter. AdvisorNet Financial Inc now owns 785 shares of the specialty chemicals company’s stock valued at $25,000 after purchasing an additional 304 shares during the last quarter. Sageworth Trust Co of South Dakota bought a new stake in Chemours in the fourth quarter valued at approximately $26,000. Steward Partners Investment Advisory LLC lifted its position in Chemours by 274.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,014 shares of the specialty chemicals company’s stock valued at $34,000 after purchasing an additional 743 shares during the last quarter. CWM LLC bought a new stake in Chemours in the fourth quarter valued at approximately $35,000. Finally, Allegheny Financial Group LTD bought a new position in shares of Chemours during the fourth quarter valued at approximately $41,000. Hedge funds and other institutional investors own 76.38% of the company’s stock.

Chemours Price Performance

Shares of CC stock opened at $34.02 on Wednesday. The stock has a market cap of $5.29 billion, a price-to-earnings ratio of 7.58, a PEG ratio of 0.47 and a beta of 1.86. The business’s fifty day moving average is $36.04 and its 200 day moving average is $33.75. The Chemours Company has a twelve month low of $22.56 and a twelve month high of $44.95. The company has a quick ratio of 1.25, a current ratio of 1.91 and a debt-to-equity ratio of 3.16.

Chemours (NYSE:CCGet Rating) last released its earnings results on Monday, May 2nd. The specialty chemicals company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.54. Chemours had a return on equity of 76.47% and a net margin of 11.19%. The firm had revenue of $1.76 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the prior year, the firm posted $0.71 earnings per share. Research analysts expect that The Chemours Company will post 5.24 EPS for the current fiscal year.

Insider Transactions at Chemours

In other news, insider Edwin C. Sparks sold 22,142 shares of the stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $43.59, for a total value of $965,169.78. Following the sale, the insider now directly owns 101,038 shares of the company’s stock, valued at $4,404,246.42. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Sameer Ralhan sold 20,175 shares of the stock in a transaction on Monday, May 9th. The stock was sold at an average price of $40.01, for a total value of $807,201.75. Following the sale, the chief financial officer now directly owns 313,506 shares of the company’s stock, valued at $12,543,375.06. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Edwin C. Sparks sold 22,142 shares of the stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $43.59, for a total value of $965,169.78. Following the sale, the insider now directly owns 101,038 shares in the company, valued at $4,404,246.42. The disclosure for this sale can be found here. Over the last three months, insiders have sold 296,280 shares of company stock valued at $11,989,133. Insiders own 3.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CC shares. UBS Group decreased their target price on Chemours to $105.00 in a report on Wednesday, July 13th. StockNews.com downgraded Chemours from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 21st. Barclays upped their target price on Chemours from $37.00 to $46.00 in a report on Monday, May 9th. Finally, Bank of America downgraded Chemours from a “buy” rating to a “neutral” rating and decreased their target price for the company from $48.00 to $44.00 in a report on Tuesday, June 14th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Chemours presently has a consensus rating of “Hold” and an average price target of $53.20.

About Chemours

(Get Rating)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Featured Articles

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CCGet Rating).

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.